Exposure to boiled peanut protein may be an improved measure for oral immunotherapy in pediatric patients, according to a new study.
[maxbutton id=”1″ url=”http://info.respiratory-therapy.com/regform” text=”SUBSCRIBE TO NEWS” ]
In results from the phase 2b/3 BOPI study, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2019 Annual Meeting in San Francisco, CA, investigators reported that three-fourths of children with peanut allergy achieved desensitization of >1.4 mg peanut protein after being administered up-dosed boiled peanut oral immunotherapy for about 6 months.
The team, led by Paul J. Turner, PhD, believe treating patients with a modified, hypoallergenic product could lead to improved desensitization.
